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Background/Aims
Diarrhea-predominant irritable bowel syndrome (IBS-D) has been previously associated with evidence of immune activation and 
altered microbiota. Our aim is to assess the effect of the anti-inflammatory agent, mesalazine, on inflammatory gene expression and 
microbiota composition in IBS-D. 
Methods
We studied a subset of patients (n = 43) from a previously published 12-week radomized placebo-controlled trial of mesalazine. 
Mucosal biopsies were assessed by immunohistochemistry and reverse transcription-polymerase chain reaction for a range of markers 
of inflammation, altered permeability, and sensory receptors including Toll-like receptors (TLRs) at randomization after treatment. All 
biopsy data were compared to 21 healthy controls. Patient’s stool microbiota composition was analysed through 16S ribosomal RNA 
sequencing.
Results
We found no evidence of increased immune activation compared to healthy controls. However, we did find increased expression of 
receptors in both sensory pathways and innate immune response including TLR4. Higher TLR4 expression was associated with greater 
urgency. TLR4 expression correlated strongly with the expression of the receptors bradykinin receptor B2, chemerin chemokine-like 
receptor 1, and transient receptor potential cation channel, subfamily A, member 1 as well as TLR4’s downstream adaptor myeloid 
differentiation factor 88. Mesalazine had minimal effect on either gene expression or microbiota composition. 
Conclusions
Biopsies from a well-characterized IBS-D cohort showed no substantial inflammation. Mesalazine has little effect on gene expression 
and its previous reported effect on fecal microbiota associated with much greater inflammation found in inflammatory bowel diseases 
is likely secondary to reduced inflammation. Increased expression of TLR4 and correlated receptors in IBS may mediate a general 
increase in sensitivity to external stimuli, particularly those that signal via the TLR system. 
(J Neurogastroenterol Motil 2021;27:279-291)
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Introduction  
Irritable bowel syndrome with diarrhea (IBS-D) is a common 
condition, affecting up to 1% of the population, characterized by 
frequent loose stools, abdominal cramps and urgency which consid-
erably impair the quality of life. Clinical diagnosis requires the ex-
clusion of a range of inflammatory conditions which closely mimic 
IBS-D, including microscopic colitis1 and Crohn’s disease, as well 
as bile salt malabsorption which is recently recognized to account 
for approximately 1 in 4 of patients presenting with symptoms of 
IBS-D.2 IBS-D can also develop after a bout of gastroenteritis, so-
called post-infectious IBS (PI-IBS).3 The risk of developing PI-
IBS is increased by the presence of markers of severity such as 
fever and rectal bleeding, suggesting that the resulting immune 
activation is a key factor in IBS symptoms.4 Both PI-IBS and other 
inflammatory conditions are associated with distinctive changes in 
microbiota.5-7 The commonest causes of PI-IBS are infections with 
either Campylobacter, Salmonella, Shigella, and Vibrio cholerae, all 
members of the Proteobacteria, which produce many toxins includ-
ing lipopolysaccharide (LPS) that act through Toll-like receptor 4 
(TLR4) to activate the cytokine cascade typical of infectious gastro-
enteritis. 
Pilot data had suggested that mesalazine, through its anti-
inflammatory actions, could normalize the underlying immune 
activation and impaired barrier function described in both PI-
IBS3,8 and IBS-D.9-11 The current work describes the baseline host 
gene expression of a range of markers of inflammation, altered 
permeability, and sensory receptors including TLRs along with the 
microbiota composition in IBS-D and their response to the anti-
inflammatory agent mesalazine. Mesalazine has been reported to 
reduce “dysbiosis” of the microbiota in patients with inflammatory 
bowel diseases (IBD), reducing the abundance of Proteobacteria 
such as Escherichia-Shigella while increasing Enterococcus, Lac-
tococcus, and Lactobacillus.12,13 It is uncertain if these changes are 
secondary to the reduction in inflammation and diarrhea or a direct 
effect of mesalazine. Mesalazine can inhibit polyphosphate kinase 
(PPK) activity, which would make the intestinal microbiome more 
sensitive to oxidative stress, reduce colonization, and diminish the 
dysbiotic microbiotas’ ability to persist in the inflamed gut.14 The 
bacteria targeted by this mechanism include Proteobacteria and 
Bacteroidetes, species often reported to be increased in the inflamed 
intestine of patients with IBD.12,15 However, inflammation on its 
own is known to alter the microbiota composition, eg, by increasing 
the colonic oxygen levels which allows facultative anaerobes, often 
reported to be increased in patients with IBD, to flourish.16,17 The 
exact effect of mesalazine on the intestinal microbiota is uncertain, 
with one small interventional study in IBS showing a reduction of 
the bacterial load by almost 50%18 while larger cross-sectional popu-
lation studies showed very little change as a consequence of taking 
mesalazine.19,20
Our aim is, therefore, to take advantage of a group of well-
characterized patients with IBS-D about to enter a clinical trial of 
mesalazine to determine (1) if inflammatory gene expression was in-
creased, (2) whether this was ameliorated by mesalazine treatment, 
and (3) if mesalazine intervention would alter fecal microbiota and 
their associations with gene expression in IBS-D. 
Materials and Methods  
Study Design
This multi-centered, parallel group, randomized placebo-
controlled trial of mesalazine 2 g twice daily for treatment of IBS-
D has been previously reported.21 Full details are available in the 
publication, but in brief, 115 patients meeting the Rome III criteria 
for IBS-D were randomized to receive either mesalazine or placebo 
for 12 weeks. Known causes of diarrhea were excluded by requiring 
patients to have a normal colonoscopy and a biopsy excluding mi-
croscopic colitis and to have either a normal selenium homocholic 
acid taurine (SeHCAT) test or negative response to cholestyramine. 
We also excluded lactose intolerance by means of a lactose challenge 
of 568 mL of skimmed milk which the patient performed at home. 
If any symptoms developed, then we performed a breath hydrogen 
lactose tolerance test using 25 g of lactose in the hospital to confirm 
the finding. A small number of patients met criteria7 for PI-IBS. 
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After documenting psychological symptoms using the Hospital 
Anxiety and Depression Scale (HADS) along with the Patient 
Health Questionnaire-12 Somatic Symptom (PHQ-12 SS) score, 
bowel frequency, stool consistency, and bowel symptoms (pain and 
urgency) were recorded daily in a diary over a 14-day period. Pain 
severity was recorded on a 0-10 scale (none––the most severe pain 
ever experienced) along with pain duration in hours/day, bloat-
ing on a 0-10 scale and the presence of urgency each day (yes/no). 
Symptoms were recorded each evening to summarize the preceding 
24 hours. 
The subgroup of patients (n = 43; Table 1), whose data is 
reported here, were those recruited in the Nottingham center who 
consented for sigmoid biopsy and stool samples prior to randomiza-
tion and at the end of the 12-week trial of either mesalazine or pla-
cebo. We also obtained sigmoid biopsies in 21 healthy volunteers, 
recruited as controls for a previous trial.22 Biopsies were obtained 
at 30 cm from the anus during an unprepared, unsedated, flexible 
sigmoidoscopy in the left lateral position. Biopsies were taken and 
processed for either immunohistochemistry or incubated in RNAl-
ater at 4℃ for 24 hours before storing frozen at –80℃ prior to as-
say. Stool samples from the patients were collected less than 2 hours 
prior to storing at –80℃. Stool samples were not collected from the 
healthy controls in the previous trial. The study was approved by 
the National Research Ethics Service (Research Ethics Committee 
reference No. 10/H0605/65) and by the Medicines and Healthcare 
Regulatory Authority (CTA reference 03057/0046/001-0001). The 
trial was registered on ClinicalTrial.gov as ISRCTN76612274. No 
change was made to the endpoints after registration. 
Laboratory Methods
Immunohistochemistry
Formalin-fixed and paraffin-embedded 4 μm sections were 
mounted on precoated slides and following dewaxing, underwent 
routine H&E staining as well as immunostaining with antibodies, 
all from Dako, Glostrup, Denmark. These included CD68 (mac-
rophage marker) and mast cell tryptase (mast cell marker). Slides 
were processed using the Dako Techmate 500 Plus and Techmate 
reagents as previously described.21
Image analysis
Slides were prepared and scanned into the computer using a 
nanozoomer displayed at ×40 magnification. Mast cell tryptase 
expression was detected in the lamina propria using automatic 
software (i-Tem Desktop by Olympus, Hamburg, Germany) as 
some mast cells were in a degranulated state, making individual 
cell counting difficult. Detection of MCT stained cell was checked 
for reproducibility (> 90%) using a standard specimen before 
cell counting began. Results were presented as the percentage area 
stained for mast cell tryptase. CD68 cells were counted in 5 high 
power fields and expressed per mm2.
Host gene expression
RNA purification.  RNA was extracted from sigmoid 
colorectal tissue biopsy and stored in RNAlater, at –80℃. RNA 
extraction was performed using TRI reagent (Pcode101078497 
T9424; Sigma Aldrich, St. Louis, MO, USA) followed by clean-
up of RNA using a Qiagen RNeasy column (Cat No 74106; Qia-
gen, Valencia, CA, USA). Synthesis of cDNA was performed us-
ing Superscript 3 reverse transcriptase according to manufacturer’s 
protocols.
Gene card. Custom-made 96 gene micro-fluidic gene cards 
(Format 96a, P/N 4342259; Applied Biosystems, Foster City, 
CA, USA) were designed to include genes associated with chronic 
inflammation, altered barrier function and nociception in IBS and 
IBD. Reference genes, which were chosen to be consistently ex-
pressed during the trial duration, included 18S RNA, beta-actin, 
ribosomal protein large PO, and hypoxanthine phosphoribosyl-
transferase 1. Gene expression values were calculated as arbitrary 
units using the geometric mean of the reference genes described 
above and calculating the 2ΔCt for each gene.23 A full list of genes, 
their abbreviations and full technical details can be found in the 
Supplementary Table 1 and Supplementary Method. 









Age (yr) 42.8 (20-75) 38.0 (19-65) 43.7 (22-69)
Sex (F/M) 16/5 13/8 13/9
Anxiety 5.20 (2.74) 7.86 (4.50) 8.00 (3.59)
Depression 1.60 (1.29) 4.67 (4.04) 4.05 (2.98)
Total HADS 6.80 (3.41) 12.52 (7.51) 12.05 (5.81)
PHQ-12 SS 2.15 (1.84) 6.67 (5.17) 4.15 (3.03)
HC, healthy controls; F, female; M, male; HADS, Hospital Anxiety and 
Depression Scale; PHQ-12 SS, Patient Health Questionnaire-12 Somatic 
Symptom score.
Anxiety and depression assessed using the HADS and PHQ-12 SS score. 
Values are expressed as mean (range), n, or mean (SD).
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Microbiota analysis
The stool microbiota DNA was extracted with a validated 
method using both mechanical as well as chemical lysis to break-
down bacterial cells.24,25 The V3-V4 hypervariable region of the 
16S rRNA gene was amplified and sequenced with the Illumina 
MiSeq platform using the standard Illumina protocol.26 As a posi-
tive sequencing control, we used the ZymoBIOMICS Microbial 
Community Standard (Cat. No. D6306; Zymo Research, Irvine, 
CA, USA) and all DNA extraction controls were sequenced to 
control for potential reagent contaminations. The composition of 
the standard sequence replicated what was reported by the provider 
and the extraction negative controls contained less than 4000 reads 
per sample, containing known reagent contaminants. The obtained 
sequence reads (on average 131 166 per sample) were prepossessed 
with Mare R package.27 In brief, the forward reads were trimmed 
to 180 nt length and to exclude sequencing errors, rare reads were 
excluded by quality filtering reads with low abundance. Chimeras 
were filtered and reads were clustered to amplicon sequence vari-
ant before taxonomical assignment using USEARCH (version 
8.1.1756) and SILVA 16S rRNA reference database version 115. 
After pre-processing, there were on average 66 718 reads per sam-
ple (ranging from 21 739 to 125 417).
Statistical Methods
All statistical methods were conducted with R (version 3.6.1). 
The histology and gene expression data were tested for normal dis-
tribution with the Shapiro–Wilk test. The significance between pa-
tients with IBS-D and healthy controls histology and gene expres-
sion was assessed by the Mann-Whitney U test and corrected for 
multiple testing with Bonferroni correction. Correlations and the 
significance of the association between gene expression and symp-
toms were measured with Spearman correlations and the statistical 
significance of the correlations was corrected for multiple testing 
with the false discovery rate (FDR) approach. Correlations over 0.35 
and with q-values less than 0.01 were considered to be significant. 
The division of samples into those with high and low TLR4 ex-
pression was set to be mean plus 1.5 times the standard deviation of 
the expression of the healthy controls as explained in Supplementary 
Figure 1.
For microbiota composition analysis, we used the following R 
packages for the microbiota analysis; mare,27 vegan,28 MASS,29 and 
nlme.28 All taxonomic ranks down to genus level taxa were used 
for statistical testing. Microbial alpha diversity was assessed using 
inverse Simpson diversity index using operational taxonomic unit 
level data. Principal coordinate analysis with Bray-Curtis dissimilar-
ities was used to visualize microbial beta diversity. To test differences 
in the bacterial abundance between study groups and the associa-
tions between the bacterial taxa and gene expression, generalized 
linear mixed models were used. In the models the read number for 
each sample was used as an offset and subjects’ age and sequencing 
batch were used as confounding factors. The obtained P-values 
were adjusted for multiple testing with the FDR approach, and 
FDR-adjusted P-values (q-values) below 0.050 were considered to 
be significant.
Results  
Baseline Comparison Between Healthy Controls and 
Patients  With Diarrhea-predominant Irritable Bowel 
Syndrome
Our patients were typical of other IBS patient series, being 
predominantly middle-aged females with mildly elevated anxiety 
and depression scores and increased non-gastroenterological symp-
toms as assessed by the PHQ-12 SS (Table 1). The PHQ was > 
6 (upper limit of normal30) in 46.9% of the patients but none of the 
controls. While 51.1% scored > 7 (upper limit of normal) on the 
anxiety scale only 32.7% were abnormal on the depression scale. As 
required for trial entry, the patients had frequent loose stools associ-
ated with bloating and abdominal pain (Table 2). Healthy controls 
were well matched with the patients for age and gender. All were 
pain-free with stool frequency median (interquartile range) of 1.0 
(1.0-1.4) /day and none met the Rome III criteria. As previously 
reported20 there were no significant differences between mesalazine 
and placebo subjects with regard to the primary endpoint, daily av-
erage stool frequency, which was (2.8; SD, 1.2) on mesalazine and 
(2.7; SD, 1.9) on placebo with adjusted between-group difference 
of 0.1 (95% CI, –0.33 to 0.53; P = 0.660). Neither were there 
Table 2. Gastrointestinal Symptoms of Patients at Randomization
GI symptoms Mesalazine Placebo
Abdominal pain severity score 4.64 (1.53) 3.32 (2.03)
Urgency 6.04 (1.65) 5.23 (2.03)
Bloating 3.71 (2.28) 3.42 (2.54)
Stool frequency/day 4.10 (1.72) 3.87 (2.21)
Stool consistency 5.44 (0.68) 5.36 (0.87)
GI, gastrointestinal.
Abdominal pain and bloating were assessed on 1-10 scale, urgency is days per 
week with urgency. Stool consistency assessed using Bristol Stool Form Score.
Values are expressed as mean (SD).
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any differences in other clinical features including abdominal pain 
severity, average stool consistency and number of days with stool 
consistency type 6-7.21
Histology
All patient biopsies had been reviewed by a pathologist (Abed 
Zaitoun) and reported as within normal limits to exclude micro-
scopic colitis prior to trial entry. Quantitative histology showed no 
evidence of inflammation. Mast cell percentage area stained was not 
elevated in these patients, mean (SD) being 2.43% (0.88) as com-
pared to 2.26% (0.79) in the controls. There were no significant dif-
ferences after 12 weeks of mesalazine 2.39% (0.69) as compared to 
placebo 2.20% (0.60). CD68 counts at baseline were slightly lower 
in the IBS-D at 1078 (415)/mm2 compared to healthy control val-
ues of 1404 (364)/mm2, P = 0.001, but at 12 weeks, there were no 
significant differences between mesalazine and controls being 1062 
(237)/mm2 and 1029 (183)/mm2, respectively. 
Difference in the Host Gene Expression Between 
Healthy Controls and Patients With Diarrhea-
predominant Irritable Bowel Syndrome
We assessed a set of genes concerned with immune activation, 
altered barrier function and response to external stimuli which we 
believed would be altered in IBS-D and whose expression may be 
modulated by mesalazine. Contrary to our original hypothesis but 
in keeping with the lack of evidence of inflammation using con-
ventional histology, we found little evidence that patients with IBS-
D had increased expression of key pro-inflammatory genes such 
as TNF-α, IL-1, and IL-6 (Supplementary Table 1). Most of 
our target genes (76/92) showed no significant difference between 
healthy controls and patients with IBS-D at baseline, however, as 
shown in Table 3, several receptors including the protease activated 
receptors coagulation factor II [thrombin] receptor-like 2 (F2RL2), 
coagulation factor II [thrombin] receptor-like 3 (F2RL3), chemer-
in chemokine-like receptor 1 (CMKLR1), and bradykinin recep-
tor B2 (BDKRB2), transient receptor potential cation channel, 
subfamily A, member 1 (TRPA1), tight junction protein 1 (TJP1), 
and TLR4 were significantly increased in IBS-D compared to our 
healthy controls.
Expression of Toll-like Receptors in Diarrhea-
predominant Irritable Bowel Syndrome 
Given the previous reports of increased TLR expression in IBS 
and patients with IBD, we assessed TLR 2, 4, 5, 7, and 9 expres-
sion in our patients at baseline which we compared with healthy 
controls; finding an increase in TLR4 only (Table 4 and Fig. 1). 
The mean gene expression value for TLR4 fell over the 12-week 
trial period in both groups, a greater numerical decrease was seen 
with mesalazine (P = 0.029) but the difference between treatment 
and placebo was not significant (P = 0.214; Fig. 2A). We found 
Table 3. Significant Gene Expression Differences Between Healthy 






ATP12A 3.52 (5.54) 0.32 (0.51) 10.93 0.001
BDKRB2 10.37 (3.35) 17.06 (6.39) 0.61 < 0.001
CMKLR1 0.77 (0.27) 1.31 (0.62) 0.59 0.003
F2RL2 0.08 (0.027) 0.17 (0.09) 0.50 0.001
F2RL3 0.29 (0.14) 0.51 (0.25) 0.57 0.006
FABP2 2.93 (1.25) 6.19 (2.75) 0.47 < 0.001
FST 0.06 (0.06) 0.11 (0.08) 0.52 0.010
IL-37 0.53 (0.25) 0.33 (0.23) 1.58 0.016
MMP2 8.31 (2.99) 12.90 (5.14) 0.64 0.007
PTGS1 2.95 (1.00) 4.20 (1.61) 0.70 0.036
TBXAS1 19.46 (51.61) 4.45 (2.20) 4.37 0.042
TGFBR1 21.31 (79.05) 4.69 (1.53) 4.55 0.049
TJP1 7.13 (2.95) 10.35 (3.08) 0.69 0.009
TLR4 1.49 (0.55) 2.56 (0.80) 0.58 < 0.001
TPH1 24.75 (44.51) 7.48 (3.01) 3.31 0.020
TRPA1 7.13 (11.02) 8.12 (3.84) 0.88 < 0.001
HC, healthy controls; IBS-D, diarrhea-predominant irritable bowel syndrome.
Gene expression measurements were calculated as 2ΔCt using the geometric 
mean of 4 reference genes described in methods and values are given as arbi-
trary units. 
For gene abreviations please see Supplementary Table 1.
Values are expressed as mean (SD).
P-values were corrected for multiple compari sons.
Table 4. Expression of Toll-like Receptors in Patients With Diarrhea-
predominant Irritable Bowel Syndrome at Baseline Compared to 
Healthy Controls 
Gene HC IBS-D P-value
TLR2 0.19 (0.08) 0.27 (0.40) 0.242
TLR4 1.49 (0.54) 2.56 (0.80) < 0.001
TLR5 0.22 (0.13) 0.29 (0.46) 0.361
TLR7 1.04 (3.06) 0.45 (0.26) 0.394
TLR9 2.07 (1.76) 1.30 (1.47) 0.092
HC, healthy controls; IBS-D, diarrhea-predominant irritable bowel syndrome; 
TLR, Toll-like receptor.
Values are expressed as mean (SD).
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no effect on any of the other TLRs examined and downstream 
genes involved in TLR signalling such as MyD88 and nucleotide-
binding oligomerization domain-containing protein 2 (NOD2) did 
not change significantly (Supplementary Fig. 2). 
Effect of Mesalazine on Gene Expression
When comparing the gene expression of mesalazine treated pa-
tients with placebo after 12 weeks, we found no significant change 
in cytokines, prostaglandins, or cyclooxygenases, which is in keep-
ing with the normal histology and lack of increased expression of 
established markers of inflammation (Supplementary Table 1). The 
only significant change in gene expression at the end of the trial be-
tween treatment and placebo was observed in TRPA1 (P = 0.018), 
which was depressed in the mesalazine treated group (Fig. 2B). 
Effect of Mesalazine Treatment on Fecal Microbiota 
Composition
The mesalazine treatment had a minimal but statistically sig-
nificant effect on the microbial composition accounting for just 4% 
of the total microbial variation. Principal coordinate analysis based 
on the distance matrix of Bray-Curtis dissimilarity showed a statisti-
cal difference between the samples at baseline and after 12 weeks 
on mesalazine treatment (P = 0.011; Fig. 3) whereas the placebo 
group was not significantly different from baseline. This observed 
difference was due to the decreased relative abundance of 9 genera 
(Table 5) within the mesalazine-treated group. Seven of these gen-
era were present at a very low abundance and hence were unlikely to 
play a major role in overall microbiota function. The 2 more abun-
dant genera that were significantly reduced after 12 weeks in the 
mesalazine treatment group were Flavonifractor and Sutterella. We 
also recorded an increase in the microbial richness in the placebo 
group after 12 weeks but not in the treated arm. We did not observe 
any statistical difference in microbial alpha diversity between the 
study groups. 
Associations Between Toll-like Receptor 4 Expression 
and Mucosal Gene-expression and Intestinal 
Microbiota
We correlated TLR4 expression with the expression of other 
mucosal genes and computed linear models to find associations be-
tween intestinal microbiota abundances. We found that the TLR4 
expression was significantly correlated with the expression of 17 










































Figure 2. Effect of mesalazine (MZ) treatment on gene expression. Only 2 genes were affected by the mesalazine treatment. (A) The expression 
of Toll-like receptor 4 was significantly reduced in the treatment group after 12 weeks (n = 21) as compared to baseline (BL; n = 22). (B) The 
transient receptor potential cation channel, subfamily A, member 1 (TRPA1) expression was significantly reduced after 12 weeks (n = 21) when 




















Figure 1. Toll-like receptor 4 expression in baseline (BL; n = 44) 
biopsy of patients with irritable bowel syndrome (IBS) is increased 
as compared to healthy controls (HC; n = 21). The line in the box 
shows the median expression value, boxes indicate the upper (75th 
percentile) and lower quartiles (25th percentile) of the data, significant 
difference between HC and patients with diarrhea-predominant IBS 
is indicated with asterisk (*P < 0.001).
285
Mesalazine, Microbiota, and Gene Expression in IBS 
Vol. 27, No. 2   April, 2021 (279-291)
measured genes (Supplementary Table 2). The strongest correla-
tions using both healthy controls and patients were those coding 
for the BDKRB2 (r = 0.58), MyD88 (r = 0.53), and CMKLR1 
(r = 0.47) receptors, all P < 0.001 (Fig. 4). TRPA1 was also sig-
nificantly correlated with TLR4 expression (r = 0.46, P < 0.001; 
Fig. 4) and was uniquely significantly reduced by mesalazine treat-
ment. 
TLR4 expression was negatively associated with the microbial 
relative abundance of the Lactobacillus (q = 0.030) and Esche-
richia/Shigella genera (q < 0.001). There was a positive association 
detected with the relative abundance of the genera, Megasphera 
(q = 0.016) and Sutterella (q = 0.022), and the class Betaproteo-
bacteria (q = 0.047). 
Link Between Gastrointestinal Symptoms and Toll-
like Receptor 4 Expression
In order to understand the relationship between TLR4 expres-
sion and patient symptoms, we subdivided the patients according to 
their TLR4 expression. The cut-off value was based on the TLR4 
expression of the healthy controls (detailed in the Materials and 
Methods section). We showed that those patients with TLR4 above 
the cut-off at baseline experienced greater number of days with 
significant urgency during the 14 days recorded in the symptom 
diary when compared with those below the cut-off (Fig. 5). How-
ever, mesalazine treatment did not reduce the number of days with 
urgency, which actually rose slightly as previously reported in the 











































Figure 3. Effect of the trial on total microbiota composition (n = 98) measured with (A) principal coordinate analysis based on the distance matrix 
of Bray-Curtis dissimilarity shows a statistical difference between the samples at baseline (BL) and after 12 weeks on mesalazine (MZ) treatment 
whereas the placebo (PL) group was not significantly different from BL, the colored circles represent 50% of the data. (B) There was a significant 
increase in microbial richness in the PL group but not MZ group after 12 weeks (*P = 0.011). 
Table 5. Genus Level Significant Differences Introduced by the Mesalazine Treatment
Bacterial taxa
Mesalazine Placebo
BL 12 wk BL 12 wk
Firmicutes; Clostridia; Clostridiales; Family XIII Incertae Sedis; Incertae Sedis 0.03 0.01a 0.02 0.02 
Firmicutes; Clostridia; Clostridiales; Heliobacteriaceae; Heliorestis 0.04 0.02a 0.01 0.01 
Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Howardella 0.04 0.01a 0.05 0.04 
Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; Flavonifractor 0.71 0.42a 1.16 1.00 
Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; Saccharofermentans 0.32 0.04a 0.03a 0.06a 
Proteobacteria; Alphaproteobacteria; Rhodospirillales; Rhodospirillaceae; Insolitispirillum 0.06 0.01a 0.06 0.04 
Proteobacteria; Betaproteobacteria; Burkholderiales; Alcaligenaceae; Sutterella 0.65 0.21a 0.79 0.27 
Proteobacteria; Deltaproteobacteria; Desulfuromonadales; Geobacteraceae; Geoalkalibacter 0.10 0.01a 0.01a 0.01a 
Tenericutes; Mollicutes; Entomoplasmatales; Spiroplasmataceae; Spiroplasma 0.03 0.00a 0.04 0.02 
aValues indicate statistically significant difference as compared to treatment arm baseline (BL) sample.
Values show the relative abundance (%) of each genus level taxon. 
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main patient group. We found no evidence of a correlation between 
TLR4 and other symptoms including pain, stool frequency, or 
bloating (P > 0.05). 
Discussion  
Here we have shown that, contrary to our initial hypothesis, 
there was no evidence of substantial immune activation in the pa-
tients with IBS. While previous reports, including our own,3,31 have 
reported increases in both mast cells and cluster of differentiation 3 
(CD3) lymphocytes, a meta-analysis32 suggests considerable hetero-
geneity, possibly because many of the studies have used unselected 
patients with IBS. Furthermore, few of the reports specifically 
exclude bile acid malabsorption and microscopic colitis as we did, 
which may possibly explain the differences from the current study. 
The other possible reason relates to the important role of psycho-





































































Figure 4. Correlations between Toll-like receptor 4 expression and gene expression of (A) chemerin chemokine-like receptor 1 (CMKLR1; r = 
0.47), (B) myeloid differentiation factor 88 (Myd88; r = 0.53), (C) bradykinin receptor B2 (BDKRB2; r = 0.58), and (D) transient receptor 
potential cation channel, subfamily A, member 1 (TRPA1; r = 0.46), all P < 0.001. BL, baseline; HC, healthy controls; MZ, mesalazine; PL, 
placebo.













Figure 5. Days/week with urgency in patients divided according to 
Toll-like receptor 4 (TLR4) expression, high = above threshold (n = 
25), low = below threshold (n = 34). Urgency was significantly less 
frequent in subjects with low TLR4 expression than in those with 
high TLR4 expression (see Methods for the threshold estimation). 
Statistical significance indicated with asterisk (*P = 0.054).
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logical distress, particularly depression, which has been shown to 
be associated with increased pro-inflammatory cytokines including 
TNF-α and IL-6. Our patients were chosen for their suitability 
for entering a clinical trial and few had significant depression, a 
fact which may also have reduced the pro-inflammatory tendency. 
None of the key pro-inflammatory genes such as TNF-α, IL-1β, 
and IL-6 were significantly increased in IBS in the current study 
compared to controls. An important limitation of our study and 
many previous studies was that the number of patients was relatively 
small, given the high degree of variability in gene expression. Us-
ing our data for IL-6 as an exemplar, at a power of 80% we could 
only detect a 2-fold change in IL-6, the main reason being the 
large standard deviation of such measures, though it is worth not-
ing that fold changes in IBD are much higher than this. We could 
not exclude smaller changes which may still have been significant. 
However, we confirmed other reports that the IBS mucosa does not 
show the type of cytokine activation seen in IBD where TNF-α 
expression for example is increased approximately 10-fold.33 Our 
study differs somewhat from another recent study which found 
increased mucosa IL-6 (9-fold), along with TLR2, TLR4, and 
C-X-C motif chemokine ligand 11 (CXCL-11) and its receptor 
CXCR-3.34 However, we did find increased expression of a range 
of receptors including BDKRB 2, fatty acid binding protein 2 
(FABP2), F2RL2, F2RL3, and CMKLR1 which rose 2-3 fold. 
This increase in receptors may be linked to a general increased sen-
sitivity to proteases that have previously been shown to be increased 
in IBS-D stool35,36 and to mediate hypersensitivity to colorectal 
distension induced in mice by patient fecal supernatants.35 They 
also mediate neural activation by IBS mucosa supernatants.37 In ad-
dition, in contrast to previous reports, we detected only a very small 
effect of mesalazine on the intestinal microbiota composition, details 
of which are discussed below. 
One of the limitations of our study was the relatively small 
number of subjects which meant that we could only detect relatively 
large changes as discussed above. The main trial reported earlier20 
did not include healthy controls so we used additional heathy sub-
jects who were recruited for another study, which did not require 
them to provide stool samples. We therefore could not benchmark 
the microbiota findings against healthy controls.
Our main trial, as previously reported, showed overall no ben-
efit from mesalazine for either pain or bowel habit,21 a finding sup-
ported by a similar trial published the same year.38 Previous studies 
attempting to define either a general gene profile in IBS39 or to test 
more specific hypotheses40-42 have failed to produce consistent find-
ings, no doubt related to the heterogeneity of IBS. One strength 
of our study is that our patients with IBS were limited to 1 subtype 
and had to meet strict criteria for entry into our clinical trial. Our 
main positive finding was increased TLR4 expression in IBS, 
which was associated with an increase in urgency and also linked to 
expression of other receptors on sensory pathways.
TLRs are recognized as an important pathway whereby both 
microbiota and food antigens43 can activate the innate immune sys-
tem. TLR4 in mice is expressed in epithelial cells and monocytes in 
the lamina propria, most markedly in the distal colon.44 Increased 
mucosal expression of TLR4 (4-5 fold), both mRNA and pro-
tein, localized to inflamed, ulcerated mucosa has been reported in 
children with IBD.45 Lesser increases of both TLR4 and TLR5 
mRNA and protein were reported in 26 patients with IBS (6 hav-
ing IBS-D)46 and of TLR2 and TLR4 mRNA and protein in 48 
patients with IBS.47 The larger Belmont study47 reported significant 
differences by subtype with a 2-fold increase in IBS-M, greater 
than in IBS-D, while Shukla et al34 found the greatest increase in 
IBS-D. We only studied IBS-D but it would be of interest to repeat 
these studies in a broader group of IBS including all subtypes to 
clarify this.
The increased expression of TLRs may underlie the exces-
sive reaction to bacterial LPS of peripheral blood monocytes with 
increased secretion of key cytokines like TNF-α, IL-6, and IL-
1β, seen in unselected IBS,48 in patients studied 6 months after 
Campylobacter jejuni infection and in patients with IBS.49 Recently 
it has been reported that IBS-D has enhanced TLR2 and TLR4 
expression which correlates with reduction of Bacteroidetes and 
Clostridium suggesting that increased expression may be a response 
to the disturbed microbiota.50
Interest in TLR activation has further been stimulated by the 
demonstration, using confocal laser endomicroscopy, that there are 
antigens in wheat, milk, and soy which can activate intra-epithelial 
lymphocytes and eosinophils in food intolerant patients with IBS, 
leading to increased small bowel permeability.43 The commonest 
food antigens implicated are wheat amylase/trypsin inhibitors,51 
which can elicit a cytokine cascade by activating TLR4 in dendritic 
cells and macrophages. Our findings suggest that patients with IBS 
may be primed to overreact to molecules in the gut which signal 
via the TLR system. How this increase is driven is unclear, but in 
Sprague-Dawley rats subject to maternal deprivation, a stress which 
is known to induce anxiety and IBS-like features, increased expres-
sion of TLR3, 4, 5, and 8 has been demonstrated.52 Whether or 
not the associated increased TLR4 in humans with IBS is due to 
such a reaction is worthy of further exploration. We found increased 
TLR4 expression was associated with increased days with urgency, 
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supporting others’ findings that TLR4 expression correlated with 
stool frequency.34 Furthermore, in a rat model mimicking IBS, with 
impaired gut barrier function and increased sensitivity to colorectal 
distension induced by a high fermentable oligosaccharides, disac-
charides, monosaccharides, and polyols (FODMAP) diet, fecal 
supernatants induced visceral hypersensitivity. This was blocked 
by small interfering RNA inhibition of TLR4 mRNA, suggest-
ing that TLR4 activation by fecal LPS could mediate visceral 
hypersensitivity.53 Animal studies using the dextran sulfate sodium 
colitis model54 do show that mesalazine reduces TLR4 expression 
associated with its anti-inflammatory effect. However, the lack of 
a significant difference from placebo in our patients suggests that 
mesalazine only reduces TLR4 expression in the presence of active 
inflammation and that this reduction is likely due to the broad anti-
inflammatory properties of mesalazine.
In this study, we observed highly significant positive cor-
relations between TLR4 and three other cell surface receptors; 
CMKLR1, TRPA1, and BDKRB2 as well as the adaptor protein 
MyD88. TLR4 activation has been shown to regulate gastroin-
testinal motility in response to gut microbial products,55 while in 
IBD, TLR4 signaling is thought to influence the intestinal micro-
biota by altering gastrointestinal motility, which drives clearance of 
pathogens and maintenance of commensal populations.56 It also 
mediates the production of defensins in response to LPS.57 Activa-
tion of TRPA1 also increases gastrointestinal motility,58 potentially 
as part of an important defence strategy against infection, leading 
to pathogen expulsion from the gut. Bradykinin is an important 
allogenic peptide that induces mechanical hyperalgesia via its 
receptor BDKRB259 which has been shown to contribute to the 
sensitivity of visceral sensory neurons to noxious chemical and me-
chanical stimuli in both mouse and human gut tissues.60,61 Thus its 
upregulation may well contribute to the hypersensitivity to disten-
sion which is so characteristic of IBS. CMKLR1, the receptor for 
chemerin, is expressed on epithelial cells and chemerin/CMKLR1 
signaling influences metabolic processes through effects on the 
gut microbiome.62 Its expression is also known to be important in 
controlling the maturation of macrophages and the balance between 
pro- and anti-inflammatory mucosal responses, but predicting how 
increased expression may alter the mucosal properties needs further 
study. FABP2 has been used as a marker of mucosal damage while 
F2RL2 and F2RL3 are protease activated receptors. Whether 
their upregulation would increase sensitivity to fecal proteases is un-
known. Others have shown fecal proteases are increased in IBS-D35 
and we have shown them to correlate with fecal urgency36 so this 
might be important. TRPA1 agonists have also been shown to in-
crease pain in experimental models of colitis.63,64 Taken together, it is 
possible that increased levels of these receptors in patients with IBS-
D may lead to increased sensitivity to external stimuli leading to 
symptoms even in the absence of any overt inflammation. Although 
MyD88 was correlated with TLR4, it was not elevated in IBS sug-
gesting that other factors are important in controlling its expression. 
One unexpected finding was the rise in TJP1. Whether this reflects 
a compensatory response to other causes of impaired barrier func-
tion that others have reported in IBS-D8-10 is unclear but one earlier 
small study suggested that this may be the case.65
While studies of microbiota in IBS are conflicting owing to lack 
of control of important factors like diet and antibiotic use, a meta-
analysis suggests that increased numbers of Proteobacteria, includ-
ing Enterobacteriaceae, and Bacteroidetes, such as Bacteroides, are 
a feature. Patients with IBS of either mixed or diarrhea subtype will 
have episodic rapid transit, which is likely to disturb the anaerobic 
colonic environment, disadvantaging the normally dominant an-
aerobes thus allowing overgrowth of the facultative, non-fastidious 
bacteria like Enterobacteriaceae. We showed that, as suggested by 
association studies of drugs and microbiota,19,20 mesalazine has only 
modest effects on the microbial composition in patients with IBS 
whose mucosa shows little evidence of inflammation. The bacterial 
taxa reduced by the treatment, Flavonifractor and Sutterella, were 
not typical potential pathogens and the changes observed could be 
due secondary to acceleration of gut transit, since loose stools are a 
recognized side effect of 5-aminosalicylic acid preparations.66 
Flavonifractor has been previously linked to IBS, being in-
creased in children with IBS in whom the amount of Flavonifractor 
was negatively associated with abdominal pain.67 Another study re-
ported this taxon was decreased in patients with IBS after increased 
rye fiber consumption,68 but similar to the current study, there was 
no association to pain. Interestingly elevated levels of Flavonifractor 
were also found in the rectal mucosa biopsies of autistic children 
with gastrointestinal disorders and pain.69 Flavonifractor can de-
grade flavonoids and polyphenolic compounds thereby increasing 
their bioavailability and beneficial effect on carbohydrate metabo-
lism70 but how this impacts on IBS symptoms remains obscure.
Olaisen and colleagues13 have also reported a reduction in 
faecal Sutterella due to mesalazine treatment. Sutterella is known 
to inhabit the small intestine, more proximally than distal, appar-
ently acting as a harmless commensal.71 Its abundance in feces is 
increased by psyllium treatment which increases colonic water.72 We 
observed a positive correlation between Betaproteobacteria, the phy-
lum to which Sutterella belongs, and TLR4 expression, though it 
is unclear if this reflects cause or effect. However, in a mouse model 
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overexpression of TLR4 resulted in increased levels of mucosal 
Proteobacteria, including Betaproteobacteria73 suggesting TLR4 
expression in mice does influence the microbiota directly. 
Previous observational studies showed that high mesalazine 
concentrations in the mucosa were associated with reduced inflam-
mation in ulcerative colitis74,75 and correlated with increased diver-
sity of the mucosa associated microbiota.13 However, there was no 
such relationship between mucosal mesalazine concentration and 
fecal microbiota, which is more relevant to our study. This suggests 
that the widespread changes in mucosal microbiota previously re-
ported with mesalazine treatment are mostly secondary to suppres-
sion of inflammation but that the effect on some, such as Sutterella, 
could be a direct effect of mesalazine. 
Our study shows clearly that, in well-defined patients with 
IBS-D who lack histological or gene expression evidence of muco-
sal inflammation, the anti-inflammatory agent mesalazine neither 
improves symptoms nor dramatically alters inflammatory gene ex-
pression nor fecal microbiota. We have in contrast shown that many 
genes controlling receptors influencing responsiveness to external 
stimuli are upregulated and these may underlie the visceral hyper-
sensitivity so typical of patients with IBS. 
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